Investigational Drug Information for Amylamine
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the development status for investigational drug Amylamine?
Amylamine is an investigational drug.
There have been 20 clinical trials for Amylamine.
The most recent clinical trial was a Phase 3 trial, which was initiated on June 13th 2019.
The most common disease conditions in clinical trials are Depressive Disorder, Depression, and Depressive Disorder, Major. The leading clinical trial sponsors are Yale University, CoMentis, and Targacept Inc.
There are two hundred and eighty-four US patents protecting this investigational drug and twenty-two international patents.
Summary for Amylamine
| US Patents | 284 |
| International Patents | 22,918 |
| US Patent Applications | 5,130 |
| WIPO Patent Applications | 261 |
| Japanese Patent Applications | 468 |
| Clinical Trial Progress | Phase 3 (2019-06-13) |
| Vendors | 55 |
Recent Clinical Trials for Amylamine
| Title | Sponsor | Phase |
|---|---|---|
| Cholinergic Mechanisms of Attention in Aging | Vanderbilt University Medical Center | Early Phase 1 |
| Clinical Study to Assess the Efficacy and Safety of AT-5214 in the Treatment of Subjects With Palmar Hyperhidrosis | Atacama Therapeutics | Phase 2 |
| Mecamylamine for Autonomic Dysreflexia Prophylaxis | Wayne State University | Phase 4 |
Clinical Trial Summary for Amylamine
Top disease conditions for Amylamine
Top clinical trial sponsors for Amylamine
US Patents for Amylamine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Amylamine | See Plans and Pricing | Template-fixed peptidomimetics | POLYPHOR LTD. (Allschwil, CH) | See Plans and Pricing |
| Amylamine | See Plans and Pricing | Cyclic amine azaheterocyclic carboxamides | Merck Patent GmbH (Darmstadt, DE) | See Plans and Pricing |
| Amylamine | See Plans and Pricing | Glycan conjugates and use thereof | ACADEMIA SINICA (Taipei, TW) | See Plans and Pricing |
| Amylamine | See Plans and Pricing | Beta-hairpin peptidomimetics as selective elastase inhibitors | POLYPHOR AG (Allschwil, CH) | See Plans and Pricing |
| Amylamine | See Plans and Pricing | Hybrid polymers, pharmaceutical compositions and methods of synthesizing the same | NEW YORK UNIVERSITY (New York, NY) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Amylamine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Amylamine | Argentina | AR054191 | 2025-05-13 | See Plans and Pricing |
| Amylamine | Australia | AU2006244851 | 2025-05-13 | See Plans and Pricing |
| Amylamine | Australia | AU2010201952 | 2025-05-13 | See Plans and Pricing |
| Amylamine | Brazil | BRPI0610279 | 2025-05-13 | See Plans and Pricing |
| Amylamine | Canada | CA2608184 | 2025-05-13 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
